Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / endostatin



This biomarker is also known as:
  • human type XVIII collagen,
  • collagen, type XVIII, alpha 1,
  • Knobloch syndrome, type 1,
  • KS,
  • multi-functional protein MFP,
  • collagen alpha-1(XVIII) chain,
  • KNO,
  • COL18A1,
  • antiangiogenic agent,
  • KNO1,

View in BioMuta


COL18A1, also known as endostatin, is the alpha chain of type XVIII collagen. COL18A1 is one of the multiplexins, extracellular matrix proteins that contain multiple triple-helix domains (collagenous domains) interrupted by non-collagenous domains. COLA18A probably plays a major role in determining the retinal structure as well as in the closure of the neural tube. It also inhibits endothelial cell proliferation and angiogenesis, and may inhibit angiogenesis by binding to the heparan sulfate proteoglycans involved in growth factor signaling.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: COL18A1


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


Endostatin, best known as an inhibitor of angiogenesis, has elevated serum levels in several cancers. Overexpression of endostatin and its parent extracellular matrix protein, collagen XVIII have been associated with poor prognosis in NSCLC (non-small cell lung cancer).

Performance Comment

Serum endostatin levels may be useful markers for NSCLC (non-small cell lung cancer). Endostatin is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.